| Project/Area Number |
16K18968
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Mukogawa Women's University |
|---|
Principal Investigator |
FUJITA MEGUMI 武庫川女子大学, 薬学部, 助教 (50509966)
|
|---|
| Research Collaborator |
MAE Saori
YAMAGUCHI Kyoko
TSUJIYA Yoshie
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | がん / 神経膠芽腫 / テモゾロミド / バルプロ酸 / 併用効果 / 浸潤 / 遊走 |
|---|
| Outline of Final Research Achievements |
Glioblastoma multiform (GBM) is most malignant in all central nervous system tumors. As invasiveness is one of the malignant characteristics of GBM, it is important to develop a novel treatment strategy. We then investigated the effects of temozolomide (TMZ) and valproic acid (VPA), which are frequently used in GBM patients as a anticancer drug and a antiepileptic drug, respectively, on cell invasion and migration in four GBM cell lines.
TMZ and VPA decreased cell invasion in T98G cells, but they tended to increase invasion and significantly increased migration in U118MG cells. The integrin cascade could be involved in these effects. However, the mechanisms was not clearly elucidated and further investigation is needed.
|
